Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (FGFR2b) Positive First-Line Gastric Cancer

June 30 (Reuters) - Zai Lab Ltd 9688.HK:

ZAI LAB ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2B (FGFR2B) POSITIVE FIRST-LINE GASTRIC CANCER

ZAI LAB LTD - PHASE 3 TRIAL MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL

ZAI LAB LTD - COMMON ADVERSE EVENTS INCLUDE REDUCED VISUAL ACUITY, ANAEMIA, NEUTROPENIA

ZAI LAB LTD - BEMARITUZUMAB PLUS CHEMOTHERAPY IMPROVES OVERALL SURVIVAL IN FGFR2B-POSITIVE GASTRIC CANCER

Source text: ID:nBw9MDLvJa

Further company coverage: 9688.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news